We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-5.2%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$642M
AUM Growth
-$8.55M
Cap. Flow
+$84.4M
Cap. Flow %
13.15%
Top 10 Hldgs %
47.56%
Holding
90
New
25
Increased
18
Reduced
19
Closed
18

Top Buys

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$30M
2
UTHR icon
United Therapeutics
UTHR
+$20.1M
3
FLXN
Flexion Therapeutics, Inc.
FLXN
+$13M
4
EPIX
ESSA Pharma
EPIX
+$10M
5
ORGO icon
Organogenesis Holdings
ORGO
+$9.94M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$18.7M
2
SKIN icon
SkinHealth Systems
SKIN
+$16.1M
3
BCAB icon
BioAtla
BCAB
+$10.9M
4
NVCR icon
NovoCure
NVCR
+$10.8M
5
ITMR
Itamar Medical Ltd. American Depository Shares
ITMR
+$7.74M

Sector Composition

Rank Sector Weight
1 Healthcare 91.89%
2 Financials 1.01%
3 Consumer Staples 0.82%
4 Real Estate 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCAB icon
1
BioAtla
BCAB
$5.59M
$74.1M 11.54%
50,308
-5,577
-10% -$10.9M
CCCC icon
2
C4 Therapeutics
CCCC
$376M
$33.5M 5.23%
750,633
-120,125
-14% -$5.14M
LNTH icon
3
Lantheus
LNTH
$6.82B
$31.6M 4.92%
1,229,827
+316,130
+35% +$8.26M
DICE
4
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$28.8M 4.49%
+879,903
New +$30M
THER
5
DELISTED
THERATECHNOLOGIES INC COM
THER
$28.5M 4.45%
7,612,383
+584,287
+8% +$2.19M
NPCE icon
6
Neuropace
NPCE
$505M
$26.5M 4.13%
1,670,136
+285,749
+21% +$6M
EPIX
7
DELISTED
ESSA Pharma
EPIX
$22.9M 3.58%
2,868,023
+629,919
+28% +$10M
SRDX
8
DELISTED
Surmodics
SRDX
$21.2M 3.31%
381,522
+103,118
+37% +$5.73M
AZN icon
9
AstraZeneca
AZN
$263B
$19.2M 2.99%
159,698
+34,625
+28% +$4.03M
FOCL
10
EDAP TMS S.A.
FOCL
$226M
$18.9M 2.94%
2,956,367
+379,966
+15% +$2.32M
UTHR icon
11
United Therapeutics
UTHR
$26.3B
$18.8M 2.93%
+101,800
New +$20.1M
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.8M 2.77%
1,093,020
-1,715,323
-61% -$18.7M
NTRA icon
13
Natera
NTRA
$37.5B
$15.5M 2.41%
138,989
+37,150
+36% +$4.26M
IRMD icon
14
iRadimed
IRMD
$1.21B
$15.1M 2.36%
450,679
-46,500
-9% -$1.58M
SIEN
15
DELISTED
Sientra, Inc.
SIEN
$13.7M 2.13%
238,606
+92,450
+63% +$6.31M
FLXN
16
DELISTED
Flexion Therapeutics, Inc.
FLXN
$12.7M 1.98%
+2,084,050
New +$13M
ENTA icon
17
Enanta Pharmaceuticals
ENTA
$372M
$10.4M 1.61%
+182,400
New +$9.02M
CRSP icon
18
CRISPR Therapeutics
CRSP
$4.58B
$10.3M 1.61%
92,214
-10,900
-11% -$1.37M
CVRX icon
19
CVRx
CVRX
$126M
$10.2M 1.6%
619,065
+192,671
+45% +$3.7M
HOWL icon
20
Werewolf Therapeutics
HOWL
$20.8M
$9.67M 1.51%
563,396
– –
NEO icon
21
NeoGenomics
NEO
$1.81B
$9.19M 1.43%
190,556
-161,451
-46% -$7.47M
ORGO icon
22
Organogenesis Holdings
ORGO
$308M
$9.11M 1.42%
+639,887
New +$9.94M
PCVX icon
23
Vaxcyte
PCVX
$7.89B
$9.02M 1.41%
355,650
-20,000
-5% -$485K
CDNA icon
24
CareDx
CDNA
$1.92B
$8.03M 1.25%
126,661
+97,361
+332% +$7.41M
NRIX icon
25
Nurix Therapeutics
NRIX
$2.43B
$7.91M 1.23%
+263,900
New +$8.14M
1
2 3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Soleus Capital Management held 90 positions worth $642M, down 1.3% from $650M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Soleus Capital Management deployed $84.4M of net new capital in Q3 2021, opening 25 new positions and adding to 18 existing holdings. Its largest new stake was DICE Therapeutics, Inc. Common Stock: 879,903 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $18.7M trimmed.

  • Soleus Capital Management's largest Q3 2021 buy was DICE Therapeutics, Inc. Common Stock: 879,903 shares worth $28.8M.
  • Soleus Capital Management added most to ESSA Pharma in Q3 2021, an estimated $10M increase.
  • Soleus Capital Management's biggest Q3 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $18.7M.
  • Soleus Capital Management fully exited MiMedx Group in Q3 2021, selling an estimated $4.03M.
  • Soleus Capital Management's ten largest holdings make up 48% of its $642M portfolio in Q3 2021.
  • Soleus Capital Management opened 25 new positions and closed 18 in Q3 2021.
  • Soleus Capital Management's portfolio value fell 1.3% quarter-over-quarter to $642M.

Based on Soleus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.